menu
    • menu
    [{"orgOrder":0,"company":"Iolyx Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ILYX-002","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Iolyx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Iolyx Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Iolyx Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iolyx Therapeutics","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"ILYX-002","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Iolyx Therapeutics","amount2":0.28000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.28000000000000003,"dosageForm":"Solution","sponsorNew":"Iolyx Therapeutics \/ Laboratoires Thea","highestDevelopmentStatusID":"8","companyTruncated":"Iolyx Therapeutics \/ Laboratoires Thea"}]

    Find Clinical Drug Pipeline Developments & Deals by Iolyx Therapeutics

    Menu

    Iolyx Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Iolyx Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Iolyx Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ILYX-002

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Laboratoires Thea

                            Deal Size : $280.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Théa Signs $280M Deal for Iolyx's Phase 3 Eye Disease Drug

                            Details : The collaboration aims to advance ILYX-002 for Dry Eye Disease (DED) treatment.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 03, 2025

                            Lead Product(s) : ILYX-002

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Laboratoires Thea

                            Deal Size : $280.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Iolyx Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Iolyx Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ILYX-002

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Iolyx Therapeutics Announces Phase 2 Results for ILYX-002 in Autoimmune Dry Eye Disease

                            Details : ILYX-002 is a topical immunomodulator, being investigated for moderate-to-severe dry eye disease (DED) associated with systemic autoimmune or inflammatory conditions.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 27, 2025

                            Lead Product(s) : ILYX-002

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth